The recent surge in investments into specialized pharmaceutical companies, particularly those focusing on experimental therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for blockbuster treatments and significant returns is clear, the connected risks are also consi… Read More